Richard B Warren

Summary

Affiliation: University of Manchester
Country: UK

Publications

  1. doi request reprint Cumulative life course impairment in psoriasis: patient perception of disease-related impairment throughout the life course
    R B Warren
    Dermatological Sciences, The University of Manchester, Manchester Academic Health Sciences Centre, Salford Royal Foundation Trust, Manchester, UK
    Br J Dermatol 164:1-14. 2011
  2. doi request reprint Adalimumab for psoriasis: practical experience in a U.K. tertiary referral centre
    R B Warren
    Dermatology Centre, Salford Royal NHS Foundation Trust, University of Manchester, Manchester Academic Health Science Centre, Manchester M6 8HD, U K
    Br J Dermatol 163:859-62. 2010
  3. doi request reprint What's new in psoriasis? Analysis of the clinical significance of new guidelines and systematic reviews on psoriasis published in 2008 and 2009
    R B Warren
    Dermatological Sciences, Salford Royal NHS Foundation Trust, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK
    Clin Exp Dermatol 35:688-91; quiz 692. 2010
  4. doi request reprint The future of biological therapies
    Richard B Warren
    Dermatology Centre, Salford Royal Hospital, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK
    Semin Cutan Med Surg 29:63-6. 2010
  5. pmc Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms
    R B Warren
    Dermatological Sciences, Salford Royal Hospital, The University of Manchester, Manchester M6 8HD, UK
    Br J Dermatol 160:438-41. 2009
  6. doi request reprint Topical treatments for scalp psoriasis
    Richard B Warren
    Dermatological Sciences, Hope Hospital, The University of Manchester, Manchester, UK
    Drugs 68:2293-302. 2008
  7. doi request reprint Biologic therapies for psoriasis: practical experience in a U.K. tertiary referral centre
    R B Warren
    Dermatological Sciences, Salford Royal Hospital, University of Manchester, Manchester M6 8HD, UK
    Br J Dermatol 160:162-9. 2009
  8. doi request reprint Methotrexate for psoriasis in the era of biological therapy
    R B Warren
    Department of Dermatological Sciences, Salford Royal Hospital, University of Manchester, Manchester, UK
    Clin Exp Dermatol 33:551-4. 2008
  9. ncbi request reprint Medical dermatology
    Richard B Warren
    Dermatological Sciences, Salford Royal Hospital, The University of Manchester
    Clin Med 8:198-200. 2008
  10. doi request reprint Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis
    Richard B Warren
    Dermatological Sciences, The University of Manchester, Salford Royal Hospital, Manchester, UK
    J Invest Dermatol 128:1925-9. 2008

Collaborators

Detail Information

Publications32

  1. doi request reprint Cumulative life course impairment in psoriasis: patient perception of disease-related impairment throughout the life course
    R B Warren
    Dermatological Sciences, The University of Manchester, Manchester Academic Health Sciences Centre, Salford Royal Foundation Trust, Manchester, UK
    Br J Dermatol 164:1-14. 2011
    ..Understanding the key risk factors for CLCI may help physicians identify patients who are more vulnerable to the cumulative impact of psoriasis, resulting in more appropriate treatment decisions earlier in the disease course...
  2. doi request reprint Adalimumab for psoriasis: practical experience in a U.K. tertiary referral centre
    R B Warren
    Dermatology Centre, Salford Royal NHS Foundation Trust, University of Manchester, Manchester Academic Health Science Centre, Manchester M6 8HD, U K
    Br J Dermatol 163:859-62. 2010
    ..There are few reports of the practical use of adalimumab outside of a clinical trial setting and, to our knowledge, none from the U.K...
  3. doi request reprint What's new in psoriasis? Analysis of the clinical significance of new guidelines and systematic reviews on psoriasis published in 2008 and 2009
    R B Warren
    Dermatological Sciences, Salford Royal NHS Foundation Trust, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK
    Clin Exp Dermatol 35:688-91; quiz 692. 2010
    ..A similar and more detailed review to this appeared in the 2009 Annual Evidence Update on Psoriasis from NHS Evidence - Skin Disorders in November 2009...
  4. doi request reprint The future of biological therapies
    Richard B Warren
    Dermatology Centre, Salford Royal Hospital, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK
    Semin Cutan Med Surg 29:63-6. 2010
    ..In this article, we discuss approaches that may be utilized to refine these existing therapies and examine future therapeutic targets for biological therapies...
  5. pmc Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms
    R B Warren
    Dermatological Sciences, Salford Royal Hospital, The University of Manchester, Manchester M6 8HD, UK
    Br J Dermatol 160:438-41. 2009
    ..Previous studies in patients with either rheumatoid arthritis or psoriasis suggest that genetic variation across the methotrexate metabolic pathway might enable prediction of both efficacy and toxicity of the drug...
  6. doi request reprint Topical treatments for scalp psoriasis
    Richard B Warren
    Dermatological Sciences, Hope Hospital, The University of Manchester, Manchester, UK
    Drugs 68:2293-302. 2008
    ..The aim of this review is to critically assess the relative effectiveness and tolerability of available topical therapies for this problematic condition and provide recommendations for selection of treatment...
  7. doi request reprint Biologic therapies for psoriasis: practical experience in a U.K. tertiary referral centre
    R B Warren
    Dermatological Sciences, Salford Royal Hospital, University of Manchester, Manchester M6 8HD, UK
    Br J Dermatol 160:162-9. 2009
    ..However, to date, there are few reports of the practical use of these therapies outside of the trial setting and, to our knowledge, none from a U.K. cohort of patients with psoriasis...
  8. doi request reprint Methotrexate for psoriasis in the era of biological therapy
    R B Warren
    Department of Dermatological Sciences, Salford Royal Hospital, University of Manchester, Manchester, UK
    Clin Exp Dermatol 33:551-4. 2008
    ..Furthermore, the potential for personalized methotrexate use by application of modern pharmacogenetics and pharmacokinetics may ensure its place as a first-line agent for the treatment of psoriasis for the foreseeable future...
  9. ncbi request reprint Medical dermatology
    Richard B Warren
    Dermatological Sciences, Salford Royal Hospital, The University of Manchester
    Clin Med 8:198-200. 2008
  10. doi request reprint Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis
    Richard B Warren
    Dermatological Sciences, The University of Manchester, Salford Royal Hospital, Manchester, UK
    J Invest Dermatol 128:1925-9. 2008
    ..2 (95% confidence interval: 1.3-3.6; P=0.001) for developing toxicity to methotrexate. These data indicate that knowledge of SNPs in genes relevant to methotrexate efflux may be important in selecting patients suitable for this therapy...
  11. doi request reprint A systematic investigation of confirmed autoimmune loci in early-onset psoriasis reveals an association with IL2/IL21
    R B Warren
    Dermatological Sciences, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester Academic Health Science Centre, UK
    Br J Dermatol 164:660-4. 2011
    ..Many autoimmune diseases share common susceptibility loci suggesting similar underlying cellular mechanisms involved in disease expression...
  12. pmc Comprehensive assessment of rheumatoid arthritis susceptibility loci in a large psoriatic arthritis cohort
    John Bowes
    Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, UK
    Ann Rheum Dis 71:1350-4. 2012
    ..Given the overlap in phenotypic expression of synovial joint inflammation between RA and psoriatic arthritis (PsA), the authors explored whether RA susceptibility genes are also associated with PsA...
  13. doi request reprint Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis
    Meghna Jani
    Centre for Musculoskeletal Research, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK Electronic address
    Lancet 385:S48. 2015
    ..Our aim was to assess whether the presence of anti-drug antibodies and non-trough drug concentrations could predict treatment response in patients with rheumatoid arthritis treated with anti-TNF drugs...
  14. doi request reprint Unmasking of axial spondyloarthritis and oligoarthritis following discontinuation of tumour necrosis factor inhibitor therapy for psoriasis
    Amy C Foulkes
    Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK
    J Dermatolog Treat 25:61-2. 2014
    ..We advocate the use of screening for psoriatic arthritis, including before and during treatment with biologic therapies. ..
  15. pmc Evidence to support IL-13 as a risk locus for psoriatic arthritis but not psoriasis vulgaris
    John Bowes
    Arthritis Research UK Epidemiology Unit, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK
    Ann Rheum Dis 70:1016-9. 2011
    ..Given this intriguing evidence, association to this gene was investigated in large collections of PsA and PsV patients and healthy controls...
  16. pmc The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases
    Meghna Jani
    Arthritis Research UK Epidemiology Unit, Manchester Academic Health Science Centre, University of Manchester, Oxford Road, Manchester M13 9PT, UK
    Rheumatology (Oxford) 53:213-22. 2014
    ..We also discuss whether such a strategy should be employed in SpA and psoriasis, and if optimization of the MTX dose could improve biologic drug survival and thereby benefit disease management...
  17. doi request reprint Ustekinumab for the treatment of psoriasis
    Philip M Laws
    Dermatological Sciences, Salford Royal Hospital, The University of Manchester, Manchester Academic Health Science Centre, Manchester, M6 8HD, UK
    Expert Rev Clin Immunol 7:155-64. 2011
    ..The currently available safety data are on the whole reassuring, although ongoing vigilance remains central to the detection of rare or late sequelae...
  18. doi request reprint Systemic therapies for psoriasis: methotrexate, retinoids, and cyclosporine
    Richard B Warren
    Dermatologic Sciences, Hope Hospital, The University of Manchester, Manchester, M6 8HD UK
    Clin Dermatol 26:438-47. 2008
    ..Ideally, cyclosporine should be used for short courses of 3 to 4 months duration, within which it provides excellent disease control. Close assessment of renal function and blood pressure is essential...
  19. doi request reprint Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
    Richard B Warren
    Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK
    J Invest Dermatol 135:2632-40. 2015
    ..48; 95% CI: 0.37-0.62). After accounting for relevant covariates, ustekinumab had the highest first-course drug survival. The results of this study will aid clinical decision making when choosing biologic therapy for psoriasis patients. ..
  20. pmc Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis
    Meghna Jani
    Meghna Jani, MBChB, MSc, MRCP Centre for Musculoskeletal Research, Institute of Inflammation and Repair, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK
    Arthritis Rheumatol 67:2011-9. 2015
    ....
  21. pmc Risk of Serious Infections in Patients with Psoriasis on Biologic Therapies: A Systematic Review and Meta-Analysis
    Zenas Z N Yiu
    Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK Centre for Pharmacoepidemiology and Drug Safety, Manchester Pharmacy School, The University of Manchester, Manchester, UK
    J Invest Dermatol 136:1584-91. 2016
    ..No association between biologic therapies and serious infections in patients with psoriasis who were eligible for RCTs was detected. Further observational studies are needed to inform the uncertainty around this risk in the real world. ..
  22. doi request reprint One SNP at a Time: Moving beyond GWAS in Psoriasis
    Helen Ray-Jones
    Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom The Dermatology Centre, Salford Royal NHS Foundation Trust, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom Electronic address
    J Invest Dermatol 136:567-73. 2016
    ..This review primarily focuses on current approaches toward gaining a complete understanding of how these known genetic loci contribute to an increased disease risk in psoriasis. ..
  23. doi request reprint Patients' narratives
    Amy C Foulkes
    Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK
    Curr Probl Dermatol 44:145-57. 2013
    ..Although longitudinal evidence to support this CLCI is lacking, these patient narratives add support to the concept of CLCI. ..
  24. doi request reprint Novel Oral Therapies for Psoriasis and Psoriatic Arthritis
    Zenas Z N Yiu
    Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester Academic Health Science Centre, The University of Manchester, Manchester, M6 8HD, UK
    Am J Clin Dermatol 17:191-200. 2016
    ..We conclude that further research and data are necessary to conclusively establish the role of these agents in the current psoriasis treatment paradigm. ..
  25. doi request reprint An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
    Richard B Warren
    Dermatology Centre, Salford Royal NHS Foundation Trust, University of Manchester and Manchester Academic Health Science Centre, Manchester, UK
    Lancet . 2016
    ..We aimed to assess the effect of an intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis...
  26. doi request reprint The potential utility of tildrakizumab: an interleukin-23 inhibitor for the treatment of psoriasis
    Zenas Z N Yiu
    a Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK
    Expert Opin Investig Drugs . 2017
    ..The low frequency of injections in the tildrakizumab maintenance regimen may encourage adherence and aid persistence...
  27. doi request reprint Safety of conventional systemic therapies for psoriasis on reproductive potential and outcomes
    Zenas Z N Yiu
    The Dermatology Centre, Salford Royal NHS Foundation Trust, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK and
    J Dermatolog Treat 26:329-34. 2015
    ..We also assess the effect of the therapies on male fertility and potential mutagenicity with paternal administration. We provide applicable guidance to inform clinician and patient before and after conception. ..
  28. doi request reprint Pharmacogenomics and the resulting impact on psoriasis therapies
    Amy C Foulkes
    The Dermatology Centre, Manchester Academic Health Science Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Salford, Manchester M6 8HD, UK
    Dermatol Clin 33:149-60. 2015
    ....
  29. pmc Identification of ZNF313/RNF114 as a novel psoriasis susceptibility gene
    Francesca Capon
    Division of Genetics and Molecular Medicine, Infection and Inflammatory Disease, King s College London, London, UK
    Hum Mol Genet 17:1938-45. 2008
    ..These findings collectively identify a novel psoriasis susceptibility gene, with a putative role in the regulation of immune responses...
  30. ncbi request reprint Polymorphisms in the IL-12beta and IL-23R genes are associated with psoriasis of early onset in a UK cohort
    Rhodri L L Smith
    J Invest Dermatol 128:1325-7. 2008
  31. ncbi request reprint Precalcaneal congenital fibrolipomatous hamartoma
    Richard B Warren
    Department of Dermatology, Royal Liverpool Children s Hospital, Liverpool, UK
    Pediatr Dermatol 24:74-5. 2007
    ..This condition is rarely reported; however, as biopsy is sometimes not performed, it may be underrepresented. We present a further histopathologically proved instance of this entity, with discussion of the differential diagnosis...